Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 13/20 | 0.48 |
| ▸ | CTSG | P08311 | 2/20 | 0.43 |
| ▸ | F11 | P03951 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
| ▸ | MC1R | Q01726 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13659873 | 0.92 | IL23R (0.45) | IL23RCTSGF11ALBPLAU | |
| SCHEMBL13649571 | 0.89 | CTSG (0.50) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL14096844 | 0.85 | ITGB3 (0.48) | CTSGALBPLAUMC4RMC5R | |
| SCHEMBL13662772 | 0.85 | ITGB3 (0.41) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL23057633 | 0.82 | ITGB3 (0.53) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL13870353 | 0.82 | ITGB3 (0.53) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL13870342 | 0.82 | ITGB3 (0.53) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL12353633 | 0.82 | MC4R (0.49) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL13287934 | 0.82 | IL23R (0.52) | IL23R | |
| SCHEMBL13870331 | 0.82 | MC4R (0.48) | CTSGPLAUMC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361443-B2 | Peptide-based compounds | GE HEALTHCARE AS (NO) | 2013-01-29 | — | — | US | disclosed |
| US-8361443-B2 | Peptide-based compounds | GE HEALTHCARE AS (NO) | 2013-01-29 | — | — | US | disclosed |
| US-20090263320-A1 | Peptide-Based Compounds | GE HEALTHCARE AS (NO) | 2009-10-22 | — | — | US | disclosed |
| US-20090263320-A1 | Peptide-Based Compounds | GE HEALTHCARE AS (NO) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263320-A1 | Peptide-Based Compounds | ITGB3, ITGAV, SELPLG | IL23R 973/4885CTSG 920/4885F11 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.